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Epilepsy is one of the most common neurologic problems worldwide. Unfortunately, individuals with epilepsy are at
higher risk of death than the general population, and sudden unexpected death in epilepsy is the most important
direct epilepsy-related cause of death. In this review article, our research group focused on the risk factors, mechanisms
and preventative measures obtained from clinical and experimental studies on sudden unexpected death in epilepsy.
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EPILEPSY: GENERAL ASPECTS
Epilepsy is one of the most prevalent neurologic condi-
tions and it knows no age, racial, social, geographic or
national boundaries.
1 In the USA, about 100,000 new cases
of epilepsy are diagnosed per year.
2,3 In the UK, at least
300,000 people are currently being treated for epilepsy.
4
From an epidemiologic point of view, some studies suggest
that between 70% and 80% of people with epilepsy will go
into remission, while the remaining patients continue to
have seizures, even under treatment with the currently
available therapies.
5–7 More consistent risk factors for
epilepsy are cerebrovascular disease, brain tumors, alcohol,
traumatic head injuries, cortical development malformation,
genetic inheritance, and infections of the central nervous
system. In resource-poor countries, endemic infections, such
as malaria and neurocysticercosis, seem to be major risk
factors.
8 By definition, epilepsies are characterized by
spontaneous recurrent seizures caused by focal or general-
ized paroxysmal changes in neurologic functions triggered
by abnormal electrical activity in the cortex.
9 As it involves
hyperexcitable neurons, a basic assumption links the
pathogenesis of epilepsy and the generation of synchro-
nized neuronal activity with an imbalance between inhibi-
tory [g-aminobutyric acid (GABA)-mediated] and excitatory
(glutamate-mediated) neurotransmission (the more favor-
able assumption).
10 In general terms, seizures and epilepsy
are usually divided into two groups: partial and general-
ized. Partial, or focal, seizures have clinical or electroence-
phalography (EEG) evidence of local onset and may spread
to other parts of the brain during a seizure, while general-
ized seizures begin simultaneously in both cerebral hemi-
spheres.
8 Although progress continues to be made in
relation to experimental design, clinical research and
medical management of epilepsy (including the develop-
ment of a number of new antiepileptic drugs),
1 epilepsy, on
the whole, remains a significant clinical problem that
requires early and effective treatment.
SUDDEN UNEXPECTED DEATH IN EPILEPSY
Overview
Although early mortality series over the past few
centuries reported deaths from status epilepticus to be more
common, deaths associated with sudden unexpected death
in epilepsy (SUDEP) were also recognized.
11 For instance,
by the afternoon of 19 June 1773, Patsy Custis was dead
at the age of 17.
12 Patsy Custis, George Washington’s
stepdaughter, died suddenly during a brief seizure, and her
death may be one of the first well-documented, witnessed
descriptions of SUDEP, unwittingly penned by George
Washington.
12 Furthermore, in 1904, Spratling described
that epilepsy ‘destroys life suddenly and without warning
through a single, brief attack…and does so in from 3 to 4% of all
who suffer from it’.
11,13 Unfortunately, this mysterious
affliction is still present today and each year about 1 in a
1000 patients with chronic epilepsy die suddenly, unexpect-
edly, and without explanation, even after postmortem
examination.
14 Thus, epilepsy is considered to be associated
with a two- to three-fold increase in mortality compared to
the general population, and SUDEP is the most important
direct epilepsy-related cause of death.
8
Definitions
The lack of autopsy findings and the rarely witnessed
cases of SUDEP pose difficulties with regard to definitions
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65of SUDEP. SUDEP was defined by precise criteria that were
approved in 1997 by an expert panel.
15 Although it has
proved useful, this workable SUDEP definition is adopted
widely, but not universally.
11 In general terms, SUDEP is
defined as sudden, unexpected, witnessed or unwitnessed,
nontraumatic and nondrowning death in patients with
epilepsy, with or without evidence of a seizure and
excluding documented status epilepticus, in which postmor-
tem examination does not reveal a toxicologic or anatomical
cause of death.
15
Incidence
The reported incidence of SUDEP is quite variable, largely
because of differences in patient populations, study design,
level of documentation and the criteria for defining
SUDEP.
16,17 To date, SUDEP is responsible for 7.5–17% of
all epilepsy deaths and has an incidence among adults of
between 15500 and 151000 patients per year.
18
Risk Factors
Whereas many disorders can be largely prevented by
avoidance or correction of risk factors, currently known risk
factors of SUDEP are not as readily modifiable for the
majority of patients.
19–21 Knowledge of the risk factors
underlying SUDEP could help investigations into its
pathophysiologic mechanisms.
22 A number of associated
factors for SUDEP have been reported but the results are not
wholly consistent between studies. In addition, epileptolo-
gists are in agreement that SUDEP is mainly, but not
exclusively, a problem for patients with chronic uncon-
trolled epilepsy.
11 The other important risk factors include
the presence of generalized tonic-clonic seizures (GTCS),
duration of the seizure disorder ranging from 15 to 20 years,
early onset of epilepsy, antiepileptic medication (polyther-
apy with antiepileptic drugs), young age and winter
temperatures.
11,22,23
Mechanisms
Understanding the mechanisms underlying SUDEP may
lead to the identification of previously unrecognized risk
factors that are more amenable to correction and key to
prevention.
11,18 Although different mechanisms may play
separate roles in different cases,
23 the two major domains of
potential mechanisms of SUDEP are autonomic, i.e. cardi-
ovascular and respiratory.
20 Pulmonary abnormalities, such
as increased lung weight, pulmonary congestion, or edema
appear frequently in postmortem examinations of SUDEP
victims.
20 Notably, both central and obstructive apnea can
occur during, or immediately after, a seizure.
24 Moreover,
obstructive apnea will usually complicate a GTCS, whereas
central apnea may occur during both partial and general-
ized seizures.
24,25 Furthermore, there are clear indications
that cardiac mechanisms play a role in SUDEP. Potential
pathomechanisms comprise cardiac arrhythmia during, and
between, seizures, antiepileptic drugs that have arrhythmo-
genic characteristics, or transmission of the epileptic activity
via the autonomic nervous system to the heart.
17 It is also
important to note that a number of postmortem, ictal and
interictal cardiac abnormalities account for the possibility of
seizure-induced cardiogenic SUDEP.
17,24 For example,
postmortem examinations in patients who died of SUDEP
have found dilated and heavier hearts than normal.
17,26,27
Furthermore, some pathologic alterations in the hearts of
patients who died of SUDEP have also been described, such
as fibrosis of the walls of small coronary arteries, cardio-
myocyte atrophy, myofibrillar degeneration, edema of the
conductive tissue and morphological abnormalities of
the cardiac conduction system.
17,26,27 These abnormalities
may be the consequence of repeated hypoxemia and/or
associated with the increase of catecholamines during ictal
sympathetic storm.
17,26,28 Several studies assessed the
frequency and character of ictal cardiac rhythm during
seizures.
17,24,26,28 The most compelling evidence derived
from the presence of ictal arrhythmias.
24 For instance,
Nashef et al. recorded non-invasively ictal cardiorespiratory
variables in patients with epilepsy.
25 The authors found
an increase in heart rate in 91% of 41 seizures monitored,
and a transient bradycardia in 5 seizures (4 patients).
25
Furthermore, Nei et al. evaluated the electrocardiographic
(ECG) changes in 51 seizures in 43 patients with refractory
epilepsy.
29 They showed that 70% of patients had either
ECG abnormalities (16%) or tachycardia (30%), or both
(23%), during the ictal and/or post-ictal period. All the
authors suggest that these changes may be relevant to the
pathophysiology of SUDEP.
29 Concerning cardiovascular
abnormalities between seizures, some research groups have
described interesting results. In 1993, Drake and co-workers
reviewed resting ECGs in 75 patients with epilepsy and
compared ventricular rate, PR interval, QRS duration, and
QT interval corrected for heart rate (QTC) with normal
ECGs recorded in age-matched patients without cardiac or
neurologic disorders.
30 Epilepsy patients showed a higher
heart rate and a longer QT duration than ECGs recorded in
age-matched patients without a cardiac or neurologic
disorder. However, heart rate and QT duration were not
outside the normal range.
30 In 2003, Tigaran et al.
investigated whether patients with drug refractory epilepsy
had cardiovascular abnormalities that may be related to a
high frequency of sudden death.
31 In their study, 23 subjects
underwent comprehensive cardiovascular evaluations
(ECG, Holter-monitoring, echocardiography, ergometric
exercise test and myocardial scintigraphy, and, if abnorm-
alities were found, coronary angiography) before and
during video-EEG monitoring. They found ST-segment
depression in 40% of patients associated with a higher
maximum heart rate during seizures, suggesting that
cardiac ischemia may occur in these patients.
31 Although
interictal changes in heart rate variability have been
described in patients with epilepsy, their contribution to
SUDEP remains to be determined.
From an experimental perspective, although much has
been learned from animal studies about structural, chemi-
cal and physiologic changes that contribute to seizures and
epilepsy, the development of experimental preparations
that closely model the human SUDEP phenomenon is
essential, as they could provide vital information to aid
elucidation of the pathogenetic mechanisms of SUDEP and
stimulate investigation into possible therapeutic strate-
gies.
32 Following this line of reasoning, the experience of
our research group makes us increasingly believe that some
chronic models of temporal lobe epilepsy are important
tools for the study of cardiovascular abnormalities in
epilepsy, and may even be relevant for understanding the
SUDEP phenomenon. In 2005, we used the pilocarpine
model in order to evaluate the heart rate of rats with
epilepsy in vivo (ECG) and in an isolated ex vivo
preparation (Langendorf preparation).
27 Briefly, we
demonstrated a significant increase in baseline heart rate
Sudden unexpected death in epilepsy
Fulvio AS et al.
CLINICS 2011;66(S1):65-69
66in vivo of animals with epilepsy [346¡7 beats per minute
(bpm)] when compared with control group animals
(307¡9 bpm). Interestingly, we did not find differences
in the isolated ex vivo studies (control animals: 175¡7b p m ;
animals with epilepsy: 176¡6 bpm), suggesting that
autonomic modulation of the heart is changed in rats with
epilepsy, which could explain the appearance and main-
tenance of an increased basal heart rate in these animals.
27
Recently, we also analyzed the heart rate in rats subjected
to electrical kindling of the amygdala.
33 The main purpose
of our study was to evaluate changes in baseline heart rate
and heart rate responses during stage 5 of kindling, which
corresponds to generalized seizures.
33 Briefly, the animals
did not show significant differences in basal heart rate
before or after electrode implantation. On the other hand,
basal heart rate was higher during stage 5 of kindling,
possibly resulting from sympathetic activation caused by
the epileptic condition. Furthermore, we also observed that
an intense bradycardia occurred at the beginning of
seizure, followed by a rebound tachycardia. Interestingly,
our results indicate that the intensity of the tachycardia is
directly related to the number of generalized seizures.
These results show that repeated GTCS directly affect
sympathetic outflows.
33
Prevention of SUDEP
Unfortunately, although we still are unable to prevent or
even completely reverse some cases of epilepsy, preventive
measures have been proposed in order to minimize the
occurrence of SUDEP,
34 although strict evidence for their
effectiveness is still lacking.
Good control of seizures is the first line of defense
The most effective conventional way to control seizures is
antiepileptic drug therapy. Medication adherence involves
factors such as getting prescriptions filled, remembering to
take medication on time and understanding the instruc-
tions. If that approach is unsuccessful, other therapies that
could be considered include epilepsy surgery and vagus
nerve stimulation.
11,23,35
Reduction of stress
The majority of studies define stress as circumstances that
people would find stressful.
36 It has been established that a
diagnosis of epilepsy may bring with it many potential stresses,
many of which are chronic.
36 The seizures, and in particular
their unpredictability, are a major source of stress for a patient
with epilepsy.
36 Furthermore, stress may cause people to forget
to take medication, leading to an increase in seizures. Stress can
t r i g g e ra ni n c r e a s ei nt h eb r e a t h ing rate (hyperventilation),
provoking seizures in certain patients, especially those with
absence seizures; negative emotions related to stress (worry or
fright) may cause seizures, especially in people with temporal
lobe epilepsy. Stress also increases cortisol levels, which may
also influence seizure activity.
36
Participation in physical activity and sports
People with epilepsy should have the same benefits as
others from the positive effects on maximal aerobic and
work capacity, body weight and self-esteem. Furthermore,
as physical activity has been considered as having an
anticonvulsant effect, it is rational to believe that regular
physical activity (with appropriate professional supervi-
sion) may attenuate the frequency of seizures and cardiac
abnormalities that could predispose patients to SUDEP.
37,38
Supervision at night
Night-time supervision involves the presence of an
individual of normal intelligence and who is at least 10
years old, or the use of special precautions (bed seizure
monitor or breathing alarm), in the bedroom.
39,40 Bed
seizure monitors or breathing alarms are designed to detect
nocturnal GTCS. These alert family members to the presence
of a seizure, allowing them to render any aid necessary in
the ictal or post-ictal settings.
39,40
Family members knowing cardiopulmonary
resuscitation (CPR) techniques and the basics of
defibrillator use
More work is required in this area; however, the use of
these techniques by trained family members can lead to
improved survival for victims of cardiac arrest that could
occur during ictal or post-ictal periods.
Omega-3 supplementation
Several experimental and clinical studies have clearly
demonstrated that complementary medical therapies,
41
especially omega-3 fatty acids, are often tried by neurologists
to control seizures.
42 The first randomized trial of omega-3
supplementation in patients with chronic epilepsy were
encouraging, demonstrating a transient effect on seizure
control that was not confirmed by other research group, but
additional trials are required.
42,43 Although these results did
not totally confirm that omega-3 fatty acids supplementation
reduced the frequency of epileptic seizures in patients with
refractory epilepsy, they established the safety of omega-3
supplementation in people with epilepsy.
42 Using the
pilocarpine model of epilepsy, a valuable tool to study the
pathogenesis of temporal lobe epilepsy in the human
condition, it was recently demonstrated that chronic treat-
ment with omega-3 promotes neuroprotection and positive
plastic changes in the brain of rats with epilepsy.
44,45 Taking
all these data together, there is now great interest in n-3 fatty
acids for use in the prevention of SUDEP.
4,46 In this sense, as
omega-3 fatty acids per se have been shown to reduce cardiac
arrhythmias and sudden cardiac deaths, it was proposed that
omega-3 fatty acid supplementation in patients with refrac-
tory seizures may reduce seizures, seizure-associated cardiac
arrhythmias and, hence, SUDEP.
4,46
The human body cannot synthesize omega-3 fatty acids so
it must be obtained from food. In fact, the intake of long-
chain omega-3 fatty acids, commonly found in fish and fish
oil, is a good way to improve the development of the brain
(from the composition of cell membranes to cerebral
function) and all omega-3 fatty acids are important for
treating or preventing cardiovascular and neurologic
diseases, including epilepsy.
4,46–49 In this context, eating
fish is a good souce of long-chain omega-3 fatty acids.
However, it is important to remember that some types of
fish (older, larger and predatory fish) may contain high
levels of contaminants, mainly methylmercury, that are
toxic to humans. Thus, the best seafood choices are those
with non-predatory characteristics (e.g. anchovies, Atlantic
herring, Atlantic mackerel, wild salmon, sardines, trout),
whilst predatory fish should be avoided (tuna, shark,
Sudden unexpected death in epilepsy
Fulvio AS et al.
CLINICS 2011;66(S1):65-69
67tilefish, swordfish).
50–53 On the other hand, for individuals
who want a diet with zero methylmercury but would like to
enjoy the benefits of omega-3 fatty acids, there are fish oil
supplements or other foods such as walnuts or oils (flax,
canola and soybean).
51,54 Despite the originality and the
health advantages of fish that are conferred by its high
omega-3 fatty acids content to patients with refractory
epilepsy, neurologists are clear that nutritional therapy is
not a substitute for anticonvulsant medications.
55
FINAL CONSIDERATIONS
Attempting to solve these problems is never an easy task;
epileptologists should establish a task force to assess the
current state of knowledge on SUDEP (clinical management,
research directions, and educational, social and cultural
efforts). Furthermore, we agree with suggestions
14 that, if
there is a reasonable chance of preventing SUDEP, it must
be discussed with all patients with epilepsy who are at
highest risk of SUDEP. Possible strategies that patients with
epilepsy and their families can take to try to reduce SUDEP
risk could then be explained by the physician.
Thus, drawing up a list of all the current problems,
evaluating the ones that merit fixing and assessing the
problems that are actually fixable should provide a
promising future. Finally, as eastern culture states: ‘Great
achievements are possible when you give importance to small
beginnings’.
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